Pathophysiology de kansè nan poumon refere a chanjman nan nòmal pwosesis fizyolojik ak mekanis ki rive nan devlopman ak pwogresyon kansè nan poumon.
Kansè poumon se yon maladi konplèks ki rive akòz kwasans ak divizyon ki pa kontwole nan selil nòmal nan poumon yo.
Selil sa yo ka fòme timè epi gaye nan lòt pati nan kò a, sa ki mennen nan plizyè sentòm ak konplikasyon.
Patofizyoloji kansè nan poumon enplike plizyè faktè, ki gen ladan mitasyon jenetik, faktè anviwònman, ak chwa fòm.
Mutasyon jenetik ka rive nan ADN nan selil poumon yo, ki mennen nan kwasans ak divizyon selil san kontwòl.
Mitasyon sa yo ka eritye oswa yo ka akeri, e yo ka koze pa ekspoze a kanserojèn, tankou lafimen tabak, radon, asbès, ak polisyon nan lè a.
Kansè poumon ka klase an de kalite prensipal: kansè poumon ti selil (SCLC) ak kansè poumon ki pa ti selil (NSCLC).
Fizyoloji patolojik tip kansè poumon sa yo kapab diferan, paske yo gen diferan mitasyon jenetik epi yo reponn yon fason diferan ak tretman.
Pathophysiology de kansè nan poumon tou enplike nan interaction ant cellules kansè yo ak tissus ki antoure yo, enkli sistèm iminitè a.
Selil kansè yo kapab evite sistèm iminitè a, sa ki pèmèt yo grandi ak pwopaje san kontwòl.
Anplis de sa, mikwo anviwònman timè a ka ankouraje kwasans timè ak metastaz lè li bay yon anviwònman ki bay sipò pou selil kansè yo.
Patofizyoloji kansè poumon se yon pwosesis konplèks ak dinamik, e chèchè yo toujou ap travay pou konprann pi byen mekanis ki kache yo pou devlope tretman ki pi efikas ak amelyore rezilta pasyan yo.
Li Z, Qian Y, Li W, Liu L, Yu L, Liu X, Wu G, Wang Y, Luo W, Fang F, Liu Y, Song F, Cai Z, Chen W, Huang W: Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening. iScience. 2020, 23 (8): 101411.
Nurwidya F, Syahruddin E, Yunus F: Pain management in lung cancer. Adv Respir Med. 2016, 84 (6): 331-336.
Khan KA, Kennedy MP, Moore E, Crush L, Prendeville S, Maher MM, Burke L, Henry MT: Radiological characteristics, histological features and clinical outcomes of lung cancer patients with coexistent idiopathic pulmonary fibrosis. Lung. 2015, 193 (1): 71-7.
Paramanantham A, Asfiya R, Das S, McCully G, Srivastava A: Extracellular Vesicle (EVs) Associated Non-Coding RNAs in Lung Cancer and Therapeutics. Int J Mol Sci. 2022, 23 (21): .
Lee D, Kim Y, Chung C: Scientific Validation and Clinical Application of Lung Cancer Organoids. Cells. 2021, 10 (11): .
Mucchietto V, Crespi A, Fasoli F, Clementi F, Gotti C: Neuronal Acetylcholine Nicotinic Receptors as New Targets for Lung Cancer Treatment. Curr Pharm Des. 2016, 22 (14): 2160-9.
['Avètisman: medikal']
['Sit entènèt sa a se pou rezon edikasyonèl ak enfòmasyon sèlman e li pa bay konsèy medikal oswa sèvis pwofesyonèl.']
['Enfòmasyon yo bay la pa dwe itilize pou fè dyagnostik oswa trete yon pwoblèm sante oswa maladi, e moun k ap chèche konsèy medikal pèsonèl ta dwe konsilte yon doktè ki gen lisans.']
['Tanpri note ke rezo neural ki jenere repons pou kesyon yo, pa egzat sitou lè li rive pou kontni nimerik. pa egzanp, kantite moun ki te dyagnostike ak yon maladi espesifik.']
['Toujou chèche konsèy doktè ou oswa lòt founisè sante ki kalifye konsènan yon kondisyon medikal. Pa janm meprize konsèy medikal pwofesyonèl oswa reta nan chèche li paske nan yon bagay ou te li sou sit entènèt sa a. Si ou panse ou ka gen yon ijans medikal, rele 911 oswa ale nan sal ijans ki pi pre a imedyatman. Pa gen okenn relasyon doktè-pasyan ki kreye pa sit entènèt sa a oswa itilizasyon li yo. Ni BioMedLib ni anplwaye li yo, ni okenn kontribitè nan sit entènèt sa a, fè okenn reprezantasyon, eksprime oswa enplisit, ki gen rapò ak enfòmasyon yo bay isit la oswa pou itilize li yo.']
['Avètisman: dwa otè']
['Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (DMCA) bay rekou pou mèt copyright ki kwè ke materyèl ki parèt sou entènèt la vyole dwa yo anba lwa copyright Etazini. ']
['Si ou kwè ak tout konfyans ke nenpòt kontni oswa materyèl ki disponib an koneksyon avèk sit entènèt nou an oswa sèvis vyole copyright ou, ou (oswa ajan ou) ka voye nou yon avi pou mande pou retire kontni an oswa materyèl la, oswa aksè a li bloke.']
['Anons yo dwe voye alekri pa imel (gade seksyon "Kontak" pou adrès imel)']
['DMCA mande pou avi ou sou vyolasyon dwa otè a genyen enfòmasyon sa yo: (1) deskripsyon travay ki gen dwa otè a ki sijè vyolasyon an; (2) deskripsyon kontni ki vyole dwa otè a ak enfòmasyon ki sifi pou pèmèt nou jwenn kontni an; (3) enfòmasyon pou kontakte ou, ki gen ladan adrès ou, nimewo telefòn ou ak adrès imel ou; (4) yon deklarasyon ou fè ki di ou gen bon lafwa ke kontni an nan fason ou pote plent la pa otorize pa mèt pwopriyete dwa otè a, oswa ajan li, oswa pa operasyon nenpòt lwa; ']
['(5) yon deklarasyon ou siyen sou penalite fo temwayaj ke enfòmasyon ki nan notifikasyon an egzat e ke ou gen otorite pou fè respekte dwa otè yo ke yo reklame ke yo vyole yo;']
['e (6) yon siyati fizik oubyen elektwonik mèt copyright la oubyen yon moun ki otorize pou aji sou non mèt copyright la. ']
['Si ou pa bay tout enfòmasyon ki anwo yo, sa ka fè ke nou pa trete plent ou a byen vit.']
['Kontak']
['Tanpri voye nou yon imèl avèk nenpòt kesyon / sijesyon.']
What is pathophysiology of lung cancer?
The pathophysiology of lung cancer refers to the changes in the normal physiological processes and mechanisms that occur in the development and progression of lung cancer.
Lung cancer is a complex disease that arises from the uncontrolled growth and division of abnormal cells in the lungs.
These cells can form tumors and spread to other parts of the body, leading to various symptoms and complications.
The pathophysiology of lung cancer involves several factors, including genetic mutations, environmental factors, and lifestyle choices.
Genetic mutations can occur in the DNA of lung cells, leading to uncontrolled cell growth and division.
These mutations can be inherited or acquired, and they can be caused by exposure to carcinogens, such as tobacco smoke, radon, asbestos, and air pollution.
Lung cancer can be classified into two main types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is further divided into three subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
The pathophysiology of these types of lung cancer can differ, as they have different genetic mutations and respond differently to treatment.
The pathophysiology of lung cancer also involves the interaction between cancer cells and the surrounding tissue, including the immune system.
Cancer cells can evade the immune system, allowing them to grow and spread unchecked.
Additionally, the tumor microenvironment can promote tumor growth and metastasis by providing a supportive environment for cancer cells.
The pathophysiology of lung cancer is a complex and dynamic process, and researchers are continuously working to better understand the underlying mechanisms to develop more effective treatments and improve patient outcomes.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['sou']
['BioMedLib itilize òdinatè otomatik (algoritm aprantisaj machin) pou jenere pè kesyon ak repons.']
['Nou kòmanse ak 35 milyon piblikasyon biomedik de PubMed/Medline. tou, paj entènèt de RefinedWeb.']
